Chimeric antigen receptors (CARs) T-cell therapy has become an important approach for cancer treatment.
Develop a novel perfusion-based, beads-free, bioreactor system as a new platform for CAR t-cell manufacturing.
The development of this novel perfusion-based system would facilitate scaling the manufacturing of CAR T cells for different users.
By implementing an automatable, scalable, and closed bioreactor-based CAR T-cell manufacturing process, an organization can reduce the cost associated with magnetic beads and manual labor, enabling broader patient access to CAR T-cell therapies and accelerating commercialization applications.
Developed an automatable, scalable, and closed bioreactor system and process for T-cell activation and expansion.
Ling, J., Fernandez, A. (May(2025)) A 3D Printed Bioreactor Enables a Closed, Streamlined Selection, Activation, Transduction, and Expansion of CAR-T Cells Without Magnetic Beads, Elsevier, https://doi.org/10.1016/j.jcyt.2025.04.039.
Ling, J., A Novel CAR T-cell Manufacturing Platform, NIIMBL National Meeting, Washington, DC, July 27, 2022.
Ling, J., Presenter, PC3.1-121 A Novel Beads-free CAR T-cell Manufacturing Platform – T cell Purification, NIIMBL National Meeting, Washington, D.C., July 27, 2022.
Fernandez, A., Bio-manufacturing of autologous CAR T cell therapies using a magnetic beads-free system, 8th Annual San Antonio Conference on Stem Cell Research and Regenerative Medicine, San Antonio, TX, February 10, 2022.
Lian, J., Presenter, A 3D Printed Bioreactor Enables a Closed, Streamlined Selection, Activation, Transduction, and Expansion of CAR-T Cells Without Magnetic Beads, International Society for Cell and Gene Therapy (ISCT), New Orleans, LA, 05/07/2025
Ling, J., A Novel Beads-free CAR T-Cell Manufacturing Platform, NIIMBL Member Forum, Virtual, March 24, 2022.
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Southwest Research Institute
Genentech, Inc.
Merck Sharp & Dohme LLC
Xcellerate Biotech Inc.
